PEB Stock Overview
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally.
Pacific Edge Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$1.24|
|52 Week High||NZ$1.59|
|52 Week Low||NZ$0.69|
|1 Month Change||-14.48%|
|3 Month Change||-7.46%|
|1 Year Change||79.71%|
|3 Year Change||254.29%|
|5 Year Change||138.46%|
|Change since IPO||608.58%|
Recent News & Updates
We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pacific Edge...
|PEB||NZ Biotechs||NZ Market|
Return vs Industry: PEB exceeded the NZ Biotechs industry which returned 4.4% over the past year.
Return vs Market: PEB exceeded the NZ Market which returned -3.4% over the past year.
|PEB Average Weekly Movement||4.8%|
|Biotechs Industry Average Movement||8.5%|
|Market Average Movement||3.5%|
|10% most volatile stocks in NZ Market||7.0%|
|10% least volatile stocks in NZ Market||2.3%|
Stable Share Price: PEB is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PEB's weekly volatility (5%) has been stable over the past year.
About the Company
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.
Pacific Edge Fundamentals Summary
|PEB fundamental statistics|
Is PEB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PEB income statement (TTM)|
|Cost of Revenue||NZ$6.00m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.02|
|Net Profit Margin||-139.90%|
How did PEB perform over the long term?See historical performance and comparison
Is Pacific Edge undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PEB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: PEB is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PEB is overvalued based on its PB Ratio (10.7x) compared to the XO Biotechs industry average (5x).
How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PEB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PEB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PEB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PEB's revenue (74.4% per year) is forecast to grow faster than the NZ market (4% per year).
High Growth Revenue: PEB's revenue (74.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PEB is forecast to be unprofitable in 3 years.
How has Pacific Edge performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PEB is currently unprofitable.
Growing Profit Margin: PEB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PEB is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (47.6%).
Return on Equity
High ROE: PEB has a negative Return on Equity (-17.25%), as it is currently unprofitable.
How is Pacific Edge's financial position?
Financial Position Analysis
Short Term Liabilities: PEB's short term assets (NZ$96.5M) exceed its short term liabilities (NZ$5.3M).
Long Term Liabilities: PEB's short term assets (NZ$96.5M) exceed its long term liabilities (NZ$1.3M).
Debt to Equity History and Analysis
Debt Level: PEB is debt free.
Reducing Debt: PEB had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PEB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PEB has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3% each year
What is Pacific Edge current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PEB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc...
Experienced Management: PEB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: PEB's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.
Pacific Edge Limited's employee growth, exchange listings and data sources
- Name: Pacific Edge Limited
- Ticker: PEB
- Exchange: NZSE
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$1.004b
- Shares outstanding: 809.41m
- Website: https://www.pacificedgedx.com
- Pacific Edge Limited
- Centre for Innovation
- 87 St David Street
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/27 06:03|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.